Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822665 · ClinicalTrials.gov registry record · Phase 4
Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT01822665 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 28 participants.
The verdict
NCT01822665, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study evaluated the effect of oral fast-dissolving formulations of paracetamol and ibuprofen on the lining of the stomach and duodenum (gastrointestinal mucosa). Endoscopic examinations were conducted to determine the gastrointestinal damage produced post a 7 day treatment regimen.
Interventions
- OTHER Placebo
- DRUG Ibuprofen
- DRUG Paracetamol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822665
The ClinicalTrials.gov registry entry for NCT01822665 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01822665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01822665 about?
NCT01822665 is a clinical study titled "Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics". This study evaluated the effect of oral fast-dissolving formulations of paracetamol and ibuprofen on the lining of the stomach and duodenum (gastrointestinal mucosa). Endoscopic examinations were conducted to determine the gastrointestinal damage produced post a 7 day treatment regimen.
What is the current status of trial NCT01822665?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2012-02. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01822665?
The interventions under investigation include: Placebo (OTHER), Ibuprofen (DRUG), Paracetamol (DRUG).
Who is sponsoring clinical trial NCT01822665?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.